To evaluate the efficacy of the treatment, as primary outcomes, two markers of circulating breast cancer, carcinoembryonic antigen (CEA) and carbohydrate antigen 15–3 (CA 15–3), were recorded. Here, CEACAM5 is linked to breast carcinoma.